Shots:

• The P-III (RUBY/ENGOT-EN6/GOG3031/NSGO) trial evaluates Jemperli + CT vs CT + PBO in patients with primary advanced or recurrent endometrial cancer. The therapy was discovered by AnaptysBio & licensed to TESARO
• The trial met its 1EPs of investigator-assessed PFS & showed a clinical benefit in the dMMR/MSI-H patient subgroup & in the overall population, PFS benefit was also seen in MMRp/MSS patient subgroup, OS data were immature & a favorable trend was observed in the overall population. The safety & tolerability profile was consistent with clinical trials of similar regimens
• The regulatory submissions are expected in H1’23 with an expected publication of full results in a medical journal & presentation at an upcoming scientific meeting

Ref: AnaptysBio | Image: GSK